Details of the Drug

General Information of Drug (ID: DM672AH)

Drug Name
Aspirin
Synonyms
ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; o-Acetoxybenzoic acid; O-Acetylsalicylic acid; Polopiryna; Acylpyrin; Ecotrin; Easprin; Acetylsalicylate; Acetophen; Acenterine; Acetosal; Colfarit; Salicylic acid acetate; o-Carboxyphenyl acetate; Enterosarein; Aspergum; Salcetogen; Pharmacin; Acetosalin; Premaspin; Micristin; Benaspir; Aspirdrops; Acetonyl; Aceticyl; Temperal; Acetylin; Empirin; Ecolen; Rhodine; Endydol; Saletin; Rheumintabletten; Solprin acid; Acidum acetylsalicylicum; Globentyl; Pravigard
Indication
Disease Entry ICD 11 Status REF
Myocardial infarction BA41-BA43 Approved [1]
Pain MG30-MG3Z Approved [2], [1]
Cardiovascular disease BA00-BE2Z Phase 3 [2], [3], [4]
Therapeutic Class
Analgesics
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 180.16
Topological Polar Surface Area (xlogp) 1.2
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 12 mL/min/kg [6]
Elimination
1.4% of drug is excreted from urine in the unchanged form [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 0.26 hours [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 370.22296 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.68% [6]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.22 L/kg [6]
Water Solubility
The ability of drug to dissolve in water is measured as 10 mg/mL [5]
Chemical Identifiers
Formula
C9H8O4
IUPAC Name
2-acetyloxybenzoic acid
Canonical SMILES
CC(=O)OC1=CC=CC=C1C(=O)O
InChI
InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
InChIKey
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2244
ChEBI ID
CHEBI:15365
CAS Number
50-78-2
DrugBank ID
DB00945
TTD ID
D0GY5Z
VARIDT ID
DR00203
INTEDE ID
DR1749
ACDINA ID
D00046

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HMG-CoA reductase (HMGCR) TTPADOQ HMDH_HUMAN Inhibitor [1]
Prostaglandin G/H synthase (COX) TTK0943 PGH1_HUMAN; PGH2_HUMAN Inhibitor [8], [1]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Probable small intestine urate exporter (SLC17A4) DTHE530 S17A4_HUMAN Substrate [9]
Sodium-dependent phosphate transport protein 1 (SLC17A1) DT8ARWJ NPT1_HUMAN Substrate [10]
Organic anion transporter 2 (SLC22A7) DT0OC1Q S22A7_HUMAN Substrate [11]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [12]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [13]
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Substrate [14]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [15]
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Substrate [16]
UDP-glucuronosyltransferase 1A6 (UGT1A6) DESD26P UD16_HUMAN Substrate [13]
N-acetyltransferase 2 (NAT2) DER7TA0 ARY2_HUMAN Substrate [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Myocardial infarction
ICD Disease Classification BA41-BA43
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
HMG-CoA reductase (HMGCR) DTT HMGCR 1.01E-05 0.65 1.53
P-glycoprotein 1 (ABCB1) DTP P-GP 3.29E-14 -7.08E-01 -1.99E+00
Probable small intestine urate exporter (SLC17A4) DTP SLC17A4 1.00E-02 -1.74E-01 -8.13E-01
Sodium-dependent phosphate transport protein 1 (SLC17A1) DTP NPT1 3.04E-01 -5.95E-02 -5.29E-01
Organic anion transporter 2 (SLC22A7) DTP OAT2 8.78E-06 -2.19E-01 -6.62E-01
Sulfotransferase 1A1 (SULT1A1) DME SULT1A1 1.61E-12 1.01E+00 1.51E+00
UDP-glucuronosyltransferase 1A1 (UGT1A1) DME UGT1A1 2.00E-01 5.79E-02 3.00E-01
N-acetyltransferase 2 (NAT2) DME NAT2 3.49E-01 -8.28E-02 -3.71E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 4.03E-02 -1.19E-01 -5.11E-01
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 2.63E-03 -1.18E-01 -3.80E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Aspirin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ibuprofen DM8VCBE Major Increased risk of bleeding by the combination of Aspirin and Ibuprofen. Pain [MG30-MG3Z] [100]
Coadministration of a Drug Treating the Disease Different from Aspirin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sodium bicarbonate DMMU6BJ Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Aspirin caused by Sodium bicarbonate mediated altered urine pH. Acidosis [5C73] [101]
Tromethamine DMOBLGK Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Aspirin caused by Tromethamine mediated altered urine pH. Acidosis [5C73] [101]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Aspirin and Glibenclamide. Acute diabete complication [5A2Y] [102]
Insulin-glulisine DMQI0FU Moderate Increased risk of hypoglycemia by the combination of Aspirin and Insulin-glulisine. Acute diabete complication [5A2Y] [103]
Insulin-aspart DMX7V28 Moderate Increased risk of hypoglycemia by the combination of Aspirin and Insulin-aspart. Acute diabete complication [5A2Y] [103]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Aspirin and Glipizide. Acute diabete complication [5A2Y] [102]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Budesonide. Asthma [CA23] [104]
Ofloxacin DM0VQN3 Moderate Additive CNS stimulant effects by the combination of Aspirin and Ofloxacin. Bacterial infection [1A00-1C4Z] [105]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Aspirin and Kanamycin. Bacterial infection [1A00-1C4Z] [106]
Sparfloxacin DMB4HCT Moderate Additive CNS stimulant effects by the combination of Aspirin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [105]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Aspirin and Streptomycin. Bacterial infection [1A00-1C4Z] [106]
Gemifloxacin DMHT34O Moderate Additive CNS stimulant effects by the combination of Aspirin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [105]
Norfloxacin DMIZ6W2 Moderate Additive CNS stimulant effects by the combination of Aspirin and Norfloxacin. Bacterial infection [1A00-1C4Z] [105]
ABT-492 DMJFD2I Moderate Additive CNS stimulant effects by the combination of Aspirin and ABT-492. Bacterial infection [1A00-1C4Z] [105]
Rabeprazole DMMZXIW Minor Decreased absorption of Aspirin due to altered gastric pH caused by Rabeprazole. Bacterial infection [1A00-1C4Z] [107]
Netilmicin DMRD1QK Moderate Increased risk of nephrotoxicity by the combination of Aspirin and Netilmicin. Bacterial infection [1A00-1C4Z] [106]
Levofloxacin DMS60RB Moderate Additive CNS stimulant effects by the combination of Aspirin and Levofloxacin. Bacterial infection [1A00-1C4Z] [108]
Lomefloxacin DMVRH9C Moderate Additive CNS stimulant effects by the combination of Aspirin and Lomefloxacin. Bacterial infection [1A00-1C4Z] [105]
Etidronic acid DM1XHYJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Etidronic acid. Bone paget disease [FB85] [109]
Ketoprofen DMRKXPT Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Ketoprofen. Chronic pain [MG30] [110]
Levomilnacipran DMV26S8 Moderate Increased risk of bleeding by the combination of Aspirin and Levomilnacipran. Chronic pain [MG30] [111]
Anisindione DM2C48U Major Increased risk of bleeding by the combination of Aspirin and Anisindione. Coagulation defect [3B10] [112]
Regorafenib DMHSY1I Major Increased risk of bleeding by the combination of Aspirin and Regorafenib. Colorectal cancer [2B91] [113]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Aspirin and Drospirenone. Contraceptive management [QA21] [114]
Ardeparin DMYRX8B Major Increased risk of bleeding by the combination of Aspirin and Ardeparin. Coronary thrombosis [BA43] [115]
Danaparoid DM6CLBN Major Increased risk of bleeding by the combination of Aspirin and Danaparoid. Deep vein thrombosis [BD71] [115]
Rivaroxaban DMQMBZ1 Major Increased risk of bleeding by the combination of Aspirin and Rivaroxaban. Deep vein thrombosis [BD71] [116]
Sertraline DM0FB1J Moderate Increased risk of bleeding by the combination of Aspirin and Sertraline. Depression [6A70-6A7Z] [111]
Vilazodone DM4LECQ Moderate Increased risk of bleeding by the combination of Aspirin and Vilazodone. Depression [6A70-6A7Z] [111]
Vortioxetine DM6F1PU Moderate Increased risk of bleeding by the combination of Aspirin and Vortioxetine. Depression [6A70-6A7Z] [111]
Milnacipran DMBFE74 Moderate Increased risk of bleeding by the combination of Aspirin and Milnacipran. Depression [6A70-6A7Z] [111]
Escitalopram DMFK9HG Moderate Increased risk of bleeding by the combination of Aspirin and Escitalopram. Depression [6A70-6A7Z] [111]
Desvenlafaxine DMHD4PE Moderate Increased risk of bleeding by the combination of Aspirin and Desvenlafaxine. Depression [6A70-6A7Z] [111]
Clomipramine DMINRKW Moderate Increased risk of bleeding by the combination of Aspirin and Clomipramine. Depression [6A70-6A7Z] [111]
Heme DMGC287 Moderate Increased risk of bleeding by the combination of Aspirin and Heme. Discovery agent [N.A.] [117]
SODIUM CITRATE DMHPD2Y Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Aspirin caused by SODIUM CITRATE mediated altered urine pH. Discovery agent [N.A.] [101]
Apigenin DMI3491 Minor Increased risk of bleeding by the combination of Aspirin and Apigenin. Discovery agent [N.A.] [118]
Fosphenytoin DMOX3LB Minor Increased plasma concentration of Aspirin and Fosphenytoin due to competitive binding of plasma proteins. Epilepsy/seizure [8A61-8A6Z] [119]
Dexlansoprazole DM1DBV5 Minor Decreased absorption of Aspirin due to altered gastric pH caused by Dexlansoprazole. Gastro-oesophageal reflux disease [DA22] [107]
Avapritinib DMK2GZX Major Increased risk of bleeding by the combination of Aspirin and Avapritinib. Gastrointestinal stromal tumour [2B5B] [113]
Brinzolamide DMBAPFG Major Increased risk of metabolic acidosis by the combination of Aspirin and Brinzolamide. Glaucoma [9C61] [120]
Dichlorphenamide DMH7IDQ Major Increased risk of metabolic acidosis by the combination of Aspirin and Dichlorphenamide. Glaucoma [9C61] [120]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Aspirin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [121]
Sodium acetate anhydrous DMH21E0 Moderate as urine pH determines the ionization state of weakly acidic or weakly alkaline drugs. Aspirin caused by Sodium acetate anhydrous mediated altered urine pH. Hypo-osmolality/hyponatraemia [5C72] [101]
Probenecid DMMFWOJ Moderate Antagonize the effect of Aspirin when combined with Probenecid. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [113]
Calaspargase pegol DMQZBXI Moderate Increased risk of bleeding by the combination of Aspirin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [122]
Acalabrutinib DM7GCVW Major Increased risk of bleeding by the combination of Aspirin and Acalabrutinib. Mature B-cell lymphoma [2A85] [123]
Ibrutinib DMHZCPO Major Increased risk of bleeding by the combination of Aspirin and Ibrutinib. Mature B-cell lymphoma [2A85] [124]
Ponatinib DMYGJQO Major Increased risk of bleeding by the combination of Aspirin and Ponatinib. Mature B-cell lymphoma [2A85] [123]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Aspirin and Exjade. Mineral absorption/transport disorder [5C64] [125]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Deflazacort. Muscular dystrophy [8C70] [104]
Prasugrel DM7MT6E Moderate Increased risk of bleeding by the combination of Aspirin and Prasugrel. Myocardial infarction [BA41-BA43] [126]
Metoclopramide DMFA5MY Minor Altered absorption of Aspirin due to GI dynamics variation caused by Metoclopramide. Nausea/vomiting [MD90] [127]
Nepafenac DMYK490 Moderate Increased risk of bleeding by the combination of Aspirin and Nepafenac. Osteoarthritis [FA00-FA05] [128]
MK-4827 DMLYGH4 Moderate Increased risk of bleeding by the combination of Aspirin and MK-4827. Ovarian cancer [2C73] [113]
Bromfenac DMKB79O Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Bromfenac. Postoperative inflammation [1A00-CA43] [110]
Epoprostenol DMUTYR2 Moderate Increased risk of bleeding by the combination of Aspirin and Epoprostenol. Pulmonary hypertension [BB01] [129]
Iloprost DMVPZBE Moderate Increased risk of bleeding by the combination of Aspirin and Iloprost. Pulmonary hypertension [BB01] [129]
Gatifloxacin DMSL679 Moderate Additive CNS stimulant effects by the combination of Aspirin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [105]
Oxaprozin DM9UB0P Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Oxaprozin. Rheumatoid arthritis [FA20] [110]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Dexamethasone. Rheumatoid arthritis [FA20] [104]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Aspirin and Leflunomide. Rheumatoid arthritis [FA20] [121]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [104]
Curcumin DMQPH29 Minor Increased risk of bleeding by the combination of Aspirin and Curcumin. Solid tumour/cancer [2A00-2F9Z] [130]
Pitolisant DM8RFNJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Aspirin and Pitolisant. Somnolence [MG42] [113]
Caplacizumab DMPUKA7 Major Increased risk of bleeding by the combination of Aspirin and Caplacizumab. Thrombocytopenia [3B64] [127]
Apixaban DM89JLN Major Increased risk of bleeding by the combination of Aspirin and Apixaban. Thrombosis [DB61-GB90] [113]
Cabozantinib DMIYDT4 Major Increased risk of bleeding by the combination of Aspirin and Cabozantinib. Thyroid cancer [2D10] [131]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Aspirin and Tolbutamide. Type 2 diabetes mellitus [5A11] [102]
Insulin-detemir DMOA4VW Moderate Increased risk of hypoglycemia by the combination of Aspirin and Insulin-detemir. Type-1/2 diabete [5A10-5A11] [103]
Insulin degludec DMPL395 Moderate Increased risk of hypoglycemia by the combination of Aspirin and Insulin degludec. Type-1/2 diabete [5A10-5A11] [103]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Aspirin and Plazomicin. Urinary tract infection [GC08] [106]
Betrixaban DM2C4RF Major Increased risk of bleeding by the combination of Aspirin and Betrixaban. Venous thromboembolism [BD72] [131]
⏷ Show the Full List of 73 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Acrylic acid E00132 6581 Other agent
Allura red AC dye E00338 33258 Colorant
Benzoic acid E00009 243 Antimicrobial preservative
Benzosulfimide E00076 5143 Flavoring agent
Butylated hydroxytoluene E00336 31404 Antioxidant
Calcium carbonate E00198 10112 Binding agent; Buffering agent; Diluent; Opacifying agent
Cholesteryl stearate E00398 118246 Emollient; Emulsifying agent
D&C red no. 27 E00381 83511 Colorant
D&C red no. 30 E00456 3000709 Colorant
Edetic acid E00094 6049 Antimicrobial preservative; Complexing agent
Ethyl acetate E00192 8857 Flavoring agent; Solvent
FD&C blue no. 1 E00263 19700 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Glyceryl monooleate E00473 5283468 Bioadhesive material; Emollient; Emulsifying agent; Emulsion stabilizing agent; Gelling agent; Modified-release agent; Surfactant
Glyceryl monostearate E00310 24699 Emollient; Emulsifying agent; Emulsion stabilizing agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Hydrazine yellow E00409 164825 Colorant
Mannitol E00103 6251 Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
methylparaben E00149 7456 Antimicrobial preservative
Propyl 4-hydroxybenzoate E00141 7175 Antimicrobial preservative
Quinoline yellow WS E00309 24671 Colorant
Saccharin sodium anhydrous E00443 656582 Flavoring agent
Saccharin sodium dihydrate E00577 46942257 Flavoring agent
Silotermo carmine G E00611 135487652 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sodium stearyl fumarate E00545 23665634 lubricant
Stearic acid E00079 5281 Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sucralose E00370 71485 Flavoring agent
Sunset yellow FCF E00255 17730 Colorant
Aluminum trihydroxide E00505 10176082 Alkalizing agent; Vaccine adjuvant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Brushite E00392 104805 Diluent
Calcium hydrogenphosphate E00294 24441 Diluent
Calcium phosphate E00298 24456 Anticaking agent; Buffering agent; Desiccant; Diluent
Carboxymethylcellulose sodium E00621 Not Available Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium E00625 Not Available Disintegrant
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Crospovidone E00626 Not Available Disintegrant
Dextrin E00359 62698 Binding agent; Diluent; Microencapsulating agent; Stiffening agent; Suspending agent; Viscosity-controlling agent
Dextrose anhydrous E00394 107526 Binding agent; Diluent; Flavoring agent; Tonicity agent
Dextrose monohydrate E00538 22814120 Binding agent; Diluent; Flavoring agent; Tonicity agent
Eisenoxyd E00585 56841934 Colorant
Elemental iron E00280 23925 Other agent
FD&C red no. 3 E00629 Not Available Colorant
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Ferrosoferric oxide E00231 14789 Colorant
Hexahydric alcohol E00083 5780 Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose E00634 Not Available Coating agent
Lithol rubin BCA E00607 135423095 Colorant
Magnesium carbonate E00205 11029 Adsorbent; Diluent
Magnesium hydroxide E00374 73981 Adsorbent; Buffering agent
Magnesium oxide E00232 14792 Anticaking agent; Diluent; Emulsifying agent; Glidant; Tonicity agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 1000 E00647 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 300 E00651 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000 E00655 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 20 E00664 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Polyvinyl alcohol E00666 Not Available Coating agent; Emulsion stabilizing agent; Film/Membrane-forming agent
Potassium hydroxide E00233 14797 Alkalizing agent
Povidone E00667 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium alginate E00671 Not Available Binding agent; Disintegrant; Suspending agent; Viscosity-controlling agent
Sodium bicarbonate E00424 516892 Alkalizing agent; Diluent
Sodium hydroxide E00234 14798 Alkalizing agent
Sorbitan monolaurate E00508 11046239 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Tartaric acid E00029 875 Acidulant; Complexing agent; Flavoring agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Triethyl citrate E00128 6506 Plasticizing agent; Solvent
Vinylpyrrolidone E00668 Not Available Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Water E00035 962 Solvent
Zinc stearate E00209 11178 lubricant
⏷ Show the Full List of 76 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Aspirin 81 mg tablet 81 mg Oral Tablet Oral
Aspirin 81 mg tablet 81 mg Delayed Release Oral Tablet Oral
Aspirin 325 mg tablet 325 mg Delayed Release Oral Tablet Oral
Aspirin 325 mg tablet 325 mg Enteric Coated Tablet Oral
Aspirin 81 mg tablet 81 mg Enteric Coated Tablet Oral
Aspirin 81 mg tablet 81 mg Delayed Release Tablet Oral
Aspirin 500 mg tablet 500 mg Oral Tablet Oral
Aspirin 300 mg tablet 300 mg Chewable Tablet Oral
Aspirin 60 mg tablet 60 mg Chewable Tablet Oral
Aspirin 81 mg tablet 81 mg Disintegrating Oral Tablet Oral
Aspirin 81 mg tablet 81 mg Chewable Tablet Oral
Aspirin 325 mg tablet 325 mg Oral Tablet Oral
Aspirin 162.5 mg capsule 162.5 mg 24 HR Extended Release Oral Capsule Oral
Aspirin 120 mg tablet 120 mg Chewable Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4139).
3 The mechanism of action of aspirin. Thromb Res. 2003 Jun 15;110(5-6):255-8.
4 Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5.
5 BDDCS applied to over 900 drugs
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Cyclooxygenase inhibitors: instrumental drugs to understand cardiovascular homeostasis and arterial thrombosis. Cardiovasc Hematol Disord Drug Targets. 2008 Dec;8(4):268-77.
9 A Na+-phosphate cotransporter homologue (SLC17A4 protein) is an intestinal organic anion exporter. Am J Physiol Cell Physiol. 2012 Jun 1;302(11):C1652-60.
10 Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem. 2010 Aug 20;285(34):26107-13.
11 Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
12 Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22.
13 Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
14 Pharmacogenomics in aspirin intolerance. Curr Drug Metab. 2009 Nov;10(9):998-1008.
15 Isozyme-specific induction of low-dose aspirin on cytochrome P450 in healthy subjects. Clin Pharmacol Ther. 2003 Mar;73(3):264-71.
16 Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
17 Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res. 2009 Mar 1;69(5):1892-900.
18 Functional characterization of human and cynomolgus monkey UDP-glucuronosyltransferase 1A1 enzymes. Life Sci. 2010 Aug 14;87(7-8):261-8.
19 Effect of UDP-glucuronosyltransferase (UGT) 1A polymorphism (rs8330 and rs10929303) on glucuronidation status of acetaminophen. Dose Response. 2017 Sep 11;15(3):1559325817723731.
20 UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80.
21 Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation. J Clin Pharmacol. 2009 Sep;49(9):1079-90.
22 Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
23 Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9.
24 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
25 Substrate-dependent modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1) by propofol in recombinant human UGT1A1 and human liver microsomes. Basic Clin Pharmacol Toxicol. 2007 Sep;101(3):211-4.
26 Identification and preliminary characterization of UDP-glucuronosyltransferases catalyzing formation of ethyl glucuronide. Anal Bioanal Chem. 2014 Apr;406(9-10):2325-32.
27 Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
28 Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
29 Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
30 Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
31 Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
32 Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94.
33 Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
34 Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23.
35 Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
36 The 2.7 A resolution structure of the glycopeptide sulfotransferase Teg14. Acta Crystallogr D Biol Crystallogr. 2010 Dec;66(Pt 12):1278-86.
37 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
38 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
39 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
40 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
41 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
42 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
43 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
44 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
45 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
46 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
47 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
48 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
49 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
50 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
51 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
52 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
53 Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol Pharmacol. 2000 Mar;57(3):468-73.
54 Importance of the evaluation of N-acetyltransferase enzyme activity prior to 5-aminosalicylic acid medication for ulcerative colitis. Inflamm Bowel Dis. 2016 Aug;22(8):1793-802.
55 N-acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes. Drug Metab Dispos. 2017 Dec;45(12):1276-1281.
56 Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099.
57 Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
58 UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab Dispos. 2011 Sep;39(9):1650-7.
59 UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S). J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6.
60 Pharmacokinetics of propofol and extrahepatic UGT1A6 gene expression in anhepatic rats. Pharmacology. 2009;84(4):219-26.
61 Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
62 S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
63 Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos. 2009 Feb;37(2):322-9.
64 Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev. 1999 Nov;31(4):817-99.
65 Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics. 2004 Aug;14(8):487-99.
66 Identification of aspartic acid and histidine residues mediating the reaction mechanism and the substrate specificity of the human UDP-glucuronosyltransferases 1A. J Biol Chem. 2007 Dec 14;282(50):36514-24.
67 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
68 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
69 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
70 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
71 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
72 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
73 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
74 Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
75 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
76 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
77 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
78 Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
79 Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8.
80 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
81 Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
82 Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
83 Mechanism of action of paracetamol. Am J Ther. 2005 Jan-Feb;12(1):46-55.
84 Diclofenac and NS-398, a selective cyclooxygenase-2 inhibitor, decrease agonist-induced contractions of the pig isolated ureter. Urol Res. 2000 Dec;28(6):376-82.
85 Comparison of the efficacy and tolerability of dexibuprofen and celecoxib in the treatment of osteoarthritis of the hip. Int J Clin Pharmacol Ther. 2003 Apr;41(4):153-64.
86 Cyclooxygenase and nitric oxide synthase dependence of cutaneous reactive hyperemia in humans. Am J Physiol Heart Circ Physiol. 2007 Jul;293(1):H425-32.
87 Interactions of PGH synthase isozymes-1 and -2 with NSAIDs. Ann N Y Acad Sci. 1994 Nov 15;744:50-7.
88 The aryl propionic acid R-flurbiprofen selectively induces p75NTR-dependent decreased survival of prostate tumor cells. Cancer Res. 2007 Apr 1;67(7):3254-62.
89 Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther. 2003 Sep;74(3):222-35.
90 The analgesic NSAID lornoxicam inhibits cyclooxygenase (COX)-1/-2, inducible nitric oxide synthase (iNOS), and the formation of interleukin (IL)-6 in vitro. Inflamm Res. 1999 Jul;48(7):369-79.
91 Modulation of arachidonic acid metabolism by orally administered morniflumate in man. Agents Actions. 1991 Jul;33(3-4):233-9.
92 Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003 Jan;44(1):409-15.
93 A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002 Jun;162(2):373-9.
94 Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes. Biopharm Drug Dispos. 2000 Dec;21(9):353-64.
95 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
96 Cholesterol-lowering effect of NK-104, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, in guinea pig model of hyperlipidemia. Arzneimittelforschung. 2001;51(3):197-203.
97 New dimension of statin action on ApoB atherogenicity. Clin Cardiol. 2003 Jan;26(1 Suppl 1):I7-10.
98 Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia. 2002 Jul-Aug;4(4):337-46.
99 Inhibitory effect of delta-tocotrienol, a HMG CoA reductase inhibitor, on monocyte-endothelial cell adhesion. J Nutr Sci Vitaminol (Tokyo). 2002 Oct;48(5):332-7.
100 Grennan DM, Ferry DG, Ashworth ME, Kenny RE, Mackinnnon M "The aspirin-ibuprofen interaction in rheumatoid arthritis." Br J Clin Pharmacol 8 (1979): 497-503. [PMID: 389264]
101 Berg KJ "Acute effects of acetylsalicylic acid in patients with chronic renal insufficiency." Eur J Clin Pharmacol 11 (1977): 111-6. [PMID: 837963]
102 Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
103 Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
104 Hansen RA, Tu W, Wang J, Ambuehl R, McDonald CJ, Murray MD "Risk of adverse gastrointestinal events from inhaled corticosteroids." Pharmacotherapy 28 (2008): 1325-34. [PMID: 18956992]
105 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
106 Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S "Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium." Clin Sci 91 (1996): 187-91. [PMID: 8795442]
107 Miner PB Jr, Fort JG, Zhang Y. Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325?mg + immediate-release omeprazole 40?mg) or enteric-coated aspirin 325?mg + enteric-coated omeprazole 40?mg - a randomised, phase 1, crossover study.?Aliment Pharmacol Ther. 2013;38(1):62-71. [PMID: 23692061]
108 Product Information. Avelox (moxifloxacin) Bayer, West Haven, CT.
109 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
110 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
111 Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
112 Barrow MV, Quick DT, Cunningham RW "Salicylate hypoprothrombinemia in rheumatoid arthritis with liver disease. Report of two cases." Arch Intern Med 120 (1967): 620-4. [PMID: 6054600]
113 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
114 Ponce SP, Jennings AE, Madias NE, Harrington JT "Drug-induced hyperkalemia." Medicine (Baltimore) 64 (1985): 357-70. [PMID: 2865667]
115 Product Information. Lovenox (enoxaparin). Rhone-Poulenc Rorer, Collegeville, PA.
116 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
117 Product Information. Panhematin (hemin). Recordati Rare Diseases Inc, Lebanon, NJ.
118 Heck AM, DeWitt BA, Lukes AL "Potential interactions between alternative therapies and warfarin." Am J Health Syst Pharm 57 (2000): 1221-7 quiz 1228-30. [PMID: 10902065]
119 Product Information. Cerebyx (fosphenytoin). Parke-Davis, Morris Plains, NJ.
120 Cowan RA, Hartnell GG, Lowdell CP, Baird IM, Leak AM "Metabolic acidosis induced by carbonic anhydrase inhibitors and salicylates in patients with normal renal function." Br Med J (Clin Res Ed) 289 (1984): 347-8. [PMID: 6432091]
121 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
122 Caruso V, Iacoviello L, Di Castelnuovo A, et.al "Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients." Blood 108 (2006): 2216-22. [PMID: 16804111]
123 Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA.
124 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
125 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
126 Product Information. Effient (prasugrel). Lilly, Eli and Company, Indianapolis, IN.
127 Cerner Multum, Inc. "Australian Product Information.".
128 Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
129 Product Information. Flolan (epoprostenol). Glaxo Wellcome, Research Triangle Park, NC.
130 Abebe W "Herbal medication: potential for adverse interactions with analgesic drugs." J Clin Pharm Ther 27 (2002): 391-401. [PMID: 12472978]
131 Bodiford AB, Kessler FO, Fermo JD, Ragucci KR "Elevated international normalized ratio with the consumption of grapefruit and use of warfarin." SAGE Open Med Case Rep 0 (2013): 1-3. [PMID: 27489634]